Published on
October 14, 2025
- 09:00 GMT
Canary Appoints Dr Michael Lincoff as Chief Clinical Officer to Lead Clinical Development of Novel siRNA Obesity Therapy
Renowned Cleveland Clinic cardiologist & lead author of the landmark SELECT trial joins Canary to advance dual gene silencing therapy CCT-217 into Phase 1 trial NEW YORK, NY, UNITED STATES, October 14, 2025 /EINPresswire.com/ -- Canary Cure …
Distribution channels:
Healthcare & Pharmaceuticals Industry, Science
...
